Qlife Holding AB

Qlife enters fully funded feasibility agreement with global pharma company for Egoo Health biomarker application

Källa: Cision
Positiv

Sammanfattning

Qlife har ingått ett fullt finansierat genomförbarhetsavtal med ett globalt läkemedelsbolag för att utvärdera en specifik biomarkör på Egoo Health. Avtalet är ett första steg mot ett potentiellt samarbete inom forskning, utveckling och framtida leverans av Egoo Health-system.

Analys

Avtalet med ett globalt läkemedelsbolag är ett strategiskt viktigt steg för Qlife, då det bekräftar intresset för Egoo Health-plattformen för dedikerade terapeutiska applikationer. Att avtalet är fullt finansierat av läkemedelsbolaget minskar Qlifes omedelbara finansiella risk. Samarbetet fokuserar på att utvärdera tekniska och integrationsfrågor, vilket kan leda till ett långsiktigt utvecklings- och leveranssamarbete. Detta stärker Qlifes partnerdrivna tillväxtmodell.

Insikter

  • • Avtalet är ett viktigt steg i Qlifes strategi att fokusera på partnerledd utveckling.
  • • Samarbetet kan leda till framtida leveransavtal för Egoo Health-system.
  • • Den strategiska betydelsen av decentraliserad biomarkörmätning lyfts fram.

Qlife Holding AB (“Qlife” or the “Company”), a pioneer in clinical-grade home diagnostics, announces that it has entered into a feasibility agreement with a global pharmaceutical company with the objective to evaluate a specific biomarker on Egoo Health related to a therapeutic application. The feasibility agreement is fully funded by the pharma company.

The feasibility study represents a first step toward a potential collaboration focused on dedicated R&D and regulatory proceedings and future supply of Egoo Health systems for the targeted application.

While the pharmaceutical partner remains undisclosed at this stage, the collaboration is anchored in a defined clinical and commercial use case where decentralized, high quality biomarker measurement is viewed as strategically important.

“This feasibility program is designed to answer the technical and integration questions required to move into a long-term development and supply collaboration. Our partner has a clear strategic interest in this application, and the structure of the project reflects that ambition.” said Thomas Warthoe, CEO of Qlife.

Strengthening Qlife’s partner driven growth model

This announcement underscores Qlife’s continued strategic focus on partner‑led development, where global pharmaceutical and diagnostics companies leverage the Egoo platform as a scalable backbone for biomarker-driven therapeutic applications.

The Company is increasingly focusing its R&D investments on co‑development models that:

  • Reduce time from feasibility to deployment
  • Enable application‑specific optimisation
  • Support long‑term supply and lifecycle collaboration

This approach allows Qlife to concentrate resources on programs with clear commercial pull and defined downstream economics.

Qlife will provide further updates as key milestones are achieved.

This disclosure contains information that Qlife Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 01-06-2026 09:00 CET.

Fler nyheter från Qlife Holding AB

Relaterade pressmeddelanden och bolagshändelser från samma bolag.

Se bolagssidan